Schroder Investment Management Group
BPMC

Schroder Investment Management Group’s Blueprint Medicines BPMC Stock Holding History

Schroder Investment Management Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,231
Closed -$908K – 1170
2025
Q1 		$908K Sell
10,231
-28,203
-73% -$2.75M ﹤0.01% 1006
2024
Q4 		$3.34M Sell
38,434
-57,865
-60% -$5.3M ﹤0.01% 846
2024
Q3 		$8.91M Buy
96,299
+72,737
+309% +$7.23M 0.01% 685
2024
Q2 		$2.54M Hold
23,562
– – ﹤0.01% 897
2024
Q1 		$2.24M Buy
23,562
+3,562
+18% +$305K ﹤0.01% 909
2023
Q4 		$1.84M Buy
+20,000
New +$1.3M ﹤0.01% 921
2023
Q1 		– Sell
-14,628
Closed -$641K – 1263
2022
Q4 		$641K Buy
+14,628
New +$702K ﹤0.01% 1107

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Schroder Investment Management Group's BPMC Position: Q2 2025 in Review

Schroder Investment Management Group sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 10,231 shares — an estimated $908K sold.

Schroder Investment Management Group first reported a position in BPMC in Q4 2022 and held it in 7 quarters. The position peaked at $8.91M in Q3 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Schroder Investment Management Group reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Schroder Investment Management Group sold 10,231 Blueprint Medicines shares in Q2 2025, an estimated $908K.
  • Schroder Investment Management Group first reported a position in Blueprint Medicines in Q4 2022 and held it in 7 quarters.
  • Schroder Investment Management Group's Blueprint Medicines position peaked at $8.91M in Q3 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Schroder Investment Management Group's 13F filing for Q2 2025, filed 13 Aug 2025.